Syntrix President John A Zebala, MD, PhD presented at the 2012 Life Science Invest Northwest (LSINW) Conference in Seattle. The Syntrix presentation featured Omnitram, the company’s new oral treatment for acute, chronic and neuropathic pain. LSINW brings together nearly 1,000 attendees from public and private companies, research institutions and the global health communit. Read about Omnitram in our pipeline.
Congratulations to Syntrix scientists on their new grant for $1.8M from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH). The project title is “Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers.” Here is the public health relevance from the proposal: “Tramadol is a widely prescribed analgesic, but 10% of the U.S. population is resistant […]
Dr. Zebala Invited to Speak at the 2011-2012 David Rogers Health Policy Colloquium at the Weill Cornell Medical College
Dr. John Zebala, President and CEO of Syntrix Biosystems and alumnus of the Weill Cornell Medical College was an invited speaker at the 2011-2012 David E. Rogers Health Policy Colloquium. Dr. Zebala shared his experience with the current business and regulatory challenges facing early-stage drug development. Learn more about the life of David E. Rogers.
Collaboration: Syntrix Receives $557K Grant to Develop New Drug for Multiple Drug Resistant Tuberculosis
Syntrix scientists will collaborate with Dr. Andrew Bognar of the University of Toronto on a $557K tuberculosis grant from the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH). The project title is “Transition-State Analogue Inhibitors of Dihydrofolate Synthetase for MDR/XDR TB.” The public health relevance from the proposal: “Multidrug-resistant tuberculosis and extensively drug […]
Congratulations to Syntrix scientists on their new grant for $3.8M from the National Hearth Lung and Blood Institute (NHBLI) of the National Institutes of Health (NIH). The project title is “Optimization of CXCR1/2 antagonist SX-576 for the treatment of BPD and COPD.” Here is the public health relevance from the proposal: “Pulmonary inflammatory diseases such as bronchopulmonary dysplasia (BPD) […]